Statins move to primary prevention (2008)
The JUPITER trial showed rosuvastatin cut heart attacks and strokes in people with normal LDL but high C-reactive protein. It challenged the idea that LDL alone decides who needs treatment. The result reached about 18,000 participants.
Guidelines and prescribing widened to include patients LDL testing had passed over.
Risk-based treatment, not a single cholesterol number, became the model for prevention.
Like JUPITER, the apoB study argues the standard number misses people who are actually at risk.
